ReP USP - Resultado da busca

Artigo de periodico
Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic (2022)
Souza, José Diogo dos Santos; Zuardi, Antonio Waldo; Guimarães, Francisco Silveira ; Osório, Flávia de Lima ; Loureiro, Sonia Regina ; Campos, Alline Cristina de; Hallak, Jaime Eduardo Cecilio ; Santos, Rafael Guimarães dos ; Silveira, Isabella Lara Machado ; Lima, Karina Pereira; Pacheco, Júlia Cozar; Ushirohira, Juliana Mayumi; Ferreira, Rafael Rinaldi; Costa, Karla Cristinne Mancini ; Scomparin, Davi Silveira; Scarante, Franciele Franco ; Santos, Isabela Pires dos; Mechoulam, Raphael; Kapczinski, Flávio; Fonseca, Benedito Antonio Lopes da; Esposito, Danillo Lucas Alves ; Andraus, Maristela Haddad; Crippa, José Alexandre de Souza
Fonte: Frontiers in Pharmacology. Unidade: FMRP
Assuntos: ANSIEDADE, DEPRESSÃO, CANABINOIDES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOUZA, José Diogo dos Santos et al. Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic. Frontiers in Pharmacology, v. 13, p. 1-9, 2022Tradução . . Disponível em: https://doi.org/10.3389/fphar.2022.856846. Acesso em: 30 jun. 2024.
APA
Souza, J. D. dos S., Zuardi, A. W., Guimarães, F. S., Osório, F. de L., Loureiro, S. R., Campos, A. C. de, et al. (2022). Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic. Frontiers in Pharmacology, 13, 1-9. doi:10.3389/fphar.2022.856846
NLM
Souza JD dos S, Zuardi AW, Guimarães FS, Osório F de L, Loureiro SR, Campos AC de, Hallak JEC, Santos RG dos, Silveira ILM, Lima KP, Pacheco JC, Ushirohira JM, Ferreira RR, Costa KCM, Scomparin DS, Scarante FF, Santos IP dos, Mechoulam R, Kapczinski F, Fonseca BAL da, Esposito DLA, Andraus MH, Crippa JA de S. Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic [Internet]. Frontiers in Pharmacology. 2022 ; 13 1-9.[citado 2024 jun. 30 ] Available from: https://doi.org/10.3389/fphar.2022.856846
Vancouver
Souza JD dos S, Zuardi AW, Guimarães FS, Osório F de L, Loureiro SR, Campos AC de, Hallak JEC, Santos RG dos, Silveira ILM, Lima KP, Pacheco JC, Ushirohira JM, Ferreira RR, Costa KCM, Scomparin DS, Scarante FF, Santos IP dos, Mechoulam R, Kapczinski F, Fonseca BAL da, Esposito DLA, Andraus MH, Crippa JA de S. Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic [Internet]. Frontiers in Pharmacology. 2022 ; 13 1-9.[citado 2024 jun. 30 ] Available from: https://doi.org/10.3389/fphar.2022.856846
Artigo de periodico
The Cannabidiol analog PECS-101 prevents chemotherapy-induced neuropathic pain via PPARγ receptors (2022)
Silva, Nicole Rodrigues; Gomes, Francisco Isaac Fernandes; Lopes, Alexandre Hashimoto Pereira; Cortez, Isadora Lopes; Santos, Jéssica Cristina dos; Silva, Conceição Elidianne Aníbal; Mechoulam, Raphael; Gomes, Felipe Villela ; Cunha, Thiago Mattar; Guimarães, Francisco Silveira
Fonte: Neurotherapeutics. Unidade: FMRP
Assuntos: ANTINEOPLÁSICOS, CANABINOIDES, GÂNGLIOS ESPINHAIS, QUIMIOTERÁPICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Nicole Rodrigues et al. The Cannabidiol analog PECS-101 prevents chemotherapy-induced neuropathic pain via PPARγ receptors. Neurotherapeutics, v. 19, n. 1, p. 434-449, 2022Tradução . . Disponível em: https://doi.org/10.1007/s13311-021-01164-w. Acesso em: 30 jun. 2024.
APA
Silva, N. R., Gomes, F. I. F., Lopes, A. H. P., Cortez, I. L., Santos, J. C. dos, Silva, C. E. A., et al. (2022). The Cannabidiol analog PECS-101 prevents chemotherapy-induced neuropathic pain via PPARγ receptors. Neurotherapeutics, 19( 1), 434-449. doi:10.1007/s13311-021-01164-w
NLM
Silva NR, Gomes FIF, Lopes AHP, Cortez IL, Santos JC dos, Silva CEA, Mechoulam R, Gomes FV, Cunha TM, Guimarães FS. The Cannabidiol analog PECS-101 prevents chemotherapy-induced neuropathic pain via PPARγ receptors [Internet]. Neurotherapeutics. 2022 ; 19( 1): 434-449.[citado 2024 jun. 30 ] Available from: https://doi.org/10.1007/s13311-021-01164-w
Vancouver
Silva NR, Gomes FIF, Lopes AHP, Cortez IL, Santos JC dos, Silva CEA, Mechoulam R, Gomes FV, Cunha TM, Guimarães FS. The Cannabidiol analog PECS-101 prevents chemotherapy-induced neuropathic pain via PPARγ receptors [Internet]. Neurotherapeutics. 2022 ; 19( 1): 434-449.[citado 2024 jun. 30 ] Available from: https://doi.org/10.1007/s13311-021-01164-w
Artigo de periodico
Cannabidiol for COVID-19 patients with mild to moderate symptoms (CANDIDATE study): a randomized, double-blind, placebo-controlled clinical trial (2022)
Crippa, José Alexandre de Souza ; Pacheco, Júlia Cozar; Zuardi, Antônio Waldo ; Guimarães, Francisco Silveira ; Campos, Alline Cristina de ; Osório, Flávia de Lima ; Loureiro, Sonia Regina ; Santos, Rafael Guimarães dos ; souza, José Diogo dos Santos; Ushirohira, Juliana Mayumi; Ferreira, Rafael Rinaldi; Costa, Karla Cristinne Mancini ; Scomparin, Davi Silveira; Scarante, Franciele Franco ; Santos, Isabela Pires dos; Mechoulam, Raphael; Kapczinski, Flávio; Fonseca, Benedito Antonio Lopes da ; Esposito, Danillo Lucas Alves ; Passos, Afonso Dinis Costa ; Dal-Fabbro, Amaury Lelis ; Bellissimo-Rodrigues, Fernando ; Arruda, Eurico ; Scarpelini, Sandro ; Andraus, Maristela Haddad; Nather Junior, Júlio Cesar; Wada, Danilo Tadao; Santos, Marcel Koenigkam ; Santos, Antonio Carlos dos ; Busatto Filho, Geraldo ; Hallak, Jaime Eduardo Cecilio
Fonte: Cannabis And Cannabinoid Research. Unidades: FMRP, FM
Assuntos: COVID-19, CANABINOIDES, ENSAIO CLÍNICO, DOENÇAS INFECCIOSAS, MEDICINA INTERNA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CRIPPA, José Alexandre de Souza et al. Cannabidiol for COVID-19 patients with mild to moderate symptoms (CANDIDATE study): a randomized, double-blind, placebo-controlled clinical trial. Cannabis And Cannabinoid Research, v. 7, n. 5, p. 658-669, 2022Tradução . . Disponível em: https://doi.org/10.1089/can.2021.0093. Acesso em: 30 jun. 2024.
APA
Crippa, J. A. de S., Pacheco, J. C., Zuardi, A. W., Guimarães, F. S., Campos, A. C. de, Osório, F. de L., et al. (2022). Cannabidiol for COVID-19 patients with mild to moderate symptoms (CANDIDATE study): a randomized, double-blind, placebo-controlled clinical trial. Cannabis And Cannabinoid Research, 7( 5), 658-669. doi:10.1089/can.2021.0093
NLM
Crippa JA de S, Pacheco JC, Zuardi AW, Guimarães FS, Campos AC de, Osório F de L, Loureiro SR, Santos RG dos, souza JD dos S, Ushirohira JM, Ferreira RR, Costa KCM, Scomparin DS, Scarante FF, Santos IP dos, Mechoulam R, Kapczinski F, Fonseca BAL da, Esposito DLA, Passos ADC, Dal-Fabbro AL, Bellissimo-Rodrigues F, Arruda E, Scarpelini S, Andraus MH, Nather Junior JC, Wada DT, Santos MK, Santos AC dos, Busatto Filho G, Hallak JEC. Cannabidiol for COVID-19 patients with mild to moderate symptoms (CANDIDATE study): a randomized, double-blind, placebo-controlled clinical trial [Internet]. Cannabis And Cannabinoid Research. 2022 ; 7( 5): 658-669.[citado 2024 jun. 30 ] Available from: https://doi.org/10.1089/can.2021.0093
Vancouver
Crippa JA de S, Pacheco JC, Zuardi AW, Guimarães FS, Campos AC de, Osório F de L, Loureiro SR, Santos RG dos, souza JD dos S, Ushirohira JM, Ferreira RR, Costa KCM, Scomparin DS, Scarante FF, Santos IP dos, Mechoulam R, Kapczinski F, Fonseca BAL da, Esposito DLA, Passos ADC, Dal-Fabbro AL, Bellissimo-Rodrigues F, Arruda E, Scarpelini S, Andraus MH, Nather Junior JC, Wada DT, Santos MK, Santos AC dos, Busatto Filho G, Hallak JEC. Cannabidiol for COVID-19 patients with mild to moderate symptoms (CANDIDATE study): a randomized, double-blind, placebo-controlled clinical trial [Internet]. Cannabis And Cannabinoid Research. 2022 ; 7( 5): 658-669.[citado 2024 jun. 30 ] Available from: https://doi.org/10.1089/can.2021.0093
Artigo de periodico
HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia (2022)
Cortez, Isadora Lopes; Silva, Nicole R.; Rodrigues, Naielly S.; Pedrazzi, João Francisco Cordeiro; Del Bel, Elaine Aparecida ; Mechoulam, Raphael; Gomes, Felipe Villela ; Guimarães, Francisco Silveira
Fonte: Progress in Neuro-Psychopharmacology and Biological Psychiatry. Unidades: FORP, FMRP
Assuntos: CANABINOIDES, ESQUIZOFRENIA, FARMACOTERAPIA, COMPORTAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CORTEZ, Isadora Lopes et al. HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, v. 117, p. 1-9, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.pnpbp.2022.110553. Acesso em: 30 jun. 2024.
APA
Cortez, I. L., Silva, N. R., Rodrigues, N. S., Pedrazzi, J. F. C., Del Bel, E. A., Mechoulam, R., et al. (2022). HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 117, 1-9. doi:10.1016/j.pnpbp.2022.110553
NLM
Cortez IL, Silva NR, Rodrigues NS, Pedrazzi JFC, Del Bel EA, Mechoulam R, Gomes FV, Guimarães FS. HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia [Internet]. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2022 ; 117 1-9.[citado 2024 jun. 30 ] Available from: https://doi.org/10.1016/j.pnpbp.2022.110553
Vancouver
Cortez IL, Silva NR, Rodrigues NS, Pedrazzi JFC, Del Bel EA, Mechoulam R, Gomes FV, Guimarães FS. HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia [Internet]. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2022 ; 117 1-9.[citado 2024 jun. 30 ] Available from: https://doi.org/10.1016/j.pnpbp.2022.110553
Artigo de periodico
Hemopressin as a breakthrough for the cannabinoid field (2021)
Heimann, Andrea S. ; Dale, Camila Squarzoni ; Guimarães, Francisco Silveira ; Reis, Ricardo A. M. ; Navon, Ami ; Shmuelov, Michal A.; Rioli, Vanessa; Gomes, Ivone; Devi, Lakshmi L.; Ferro, Emer Suavinho
Fonte: Neuropharmacology. Unidades: ICB, FMRP
Assuntos: ANATOMIA, FARMACOLOGIA, CANABINOIDES, RECEPTORES, PEPTÍDEOS, HEMOGLOBINAS, CAMUNDONGOS, MITOCÔNDRIAS, ANTI-INFLAMATÓRIOS, MATERIAIS NANOESTRUTURADOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HEIMANN, Andrea S. et al. Hemopressin as a breakthrough for the cannabinoid field. Neuropharmacology, v. 183, p. 12 , 2021Tradução . . Disponível em: https://doi.org/10.1016/j.neuropharm.2020.108406. Acesso em: 30 jun. 2024.
APA
Heimann, A. S., Dale, C. S., Guimarães, F. S., Reis, R. A. M., Navon, A., Shmuelov, M. A., et al. (2021). Hemopressin as a breakthrough for the cannabinoid field. Neuropharmacology, 183, 12 . doi:10.1016/j.neuropharm.2020.108406
NLM
Heimann AS, Dale CS, Guimarães FS, Reis RAM, Navon A, Shmuelov MA, Rioli V, Gomes I, Devi LL, Ferro ES. Hemopressin as a breakthrough for the cannabinoid field [Internet]. Neuropharmacology. 2021 ; 183 12 .[citado 2024 jun. 30 ] Available from: https://doi.org/10.1016/j.neuropharm.2020.108406
Vancouver
Heimann AS, Dale CS, Guimarães FS, Reis RAM, Navon A, Shmuelov MA, Rioli V, Gomes I, Devi LL, Ferro ES. Hemopressin as a breakthrough for the cannabinoid field [Internet]. Neuropharmacology. 2021 ; 183 12 .[citado 2024 jun. 30 ] Available from: https://doi.org/10.1016/j.neuropharm.2020.108406
Artigo de periodico
Efficacy and safety of cannabidiol plus standard care vs standard care alone for the treatment of emotional exhaustion and Burnout among frontline health care workers during the COVID-19 pandemic: a randomized clinical trial (2021)
Crippa, José Alexandre de Souza ; Zuardi, Antonio Waldo; Guimarães, Francisco Silveira ; Campos, Alline Cristina de; Osório, Flávia de Lima ; Loureiro, Sonia Regina ; Santos, Rafael Guimarães dos ; Souza, José Diogo dos Santos; Ushirohira, Juliana Mayumi; Pacheco, Júlia Cozar; Ferreira, Rafael Rinaldi; Costa, Karla Cristinne Mancini ; Scomparin, Davi Silveira; Scarante, Franciele Franco ; Santos, Isabela Pires dos; Mechoulam, Raphael; Kapczinski, Flávio; Fonseca, Benedito Antonio Lopes da; Esposito, Danillo Lucas Alves ; Lima, Karina Pereira; Sen, Srijan; Andraus, Maristela Haddad; Hallak, Jaime Eduardo Cecilio
Fonte: JAMA Network Open. Unidade: FMRP
Assuntos: CANABINOIDES, ANSIOLÍTICOS, ESTRESSE PROFISSIONAL, EQUIPE DE ASSISTÊNCIA AO PACIENTE, COVID-19, FARMACOTERAPIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CRIPPA, José Alexandre de Souza et al. Efficacy and safety of cannabidiol plus standard care vs standard care alone for the treatment of emotional exhaustion and Burnout among frontline health care workers during the COVID-19 pandemic: a randomized clinical trial. JAMA Network Open, v. 4, n. 8, 2021Tradução . . Disponível em: https://doi.org/10.1001/jamanetworkopen.2021.20603. Acesso em: 30 jun. 2024.
APA
Crippa, J. A. de S., Zuardi, A. W., Guimarães, F. S., Campos, A. C. de, Osório, F. de L., Loureiro, S. R., et al. (2021). Efficacy and safety of cannabidiol plus standard care vs standard care alone for the treatment of emotional exhaustion and Burnout among frontline health care workers during the COVID-19 pandemic: a randomized clinical trial. JAMA Network Open, 4( 8). doi:10.1001/jamanetworkopen.2021.20603
NLM
Crippa JA de S, Zuardi AW, Guimarães FS, Campos AC de, Osório F de L, Loureiro SR, Santos RG dos, Souza JD dos S, Ushirohira JM, Pacheco JC, Ferreira RR, Costa KCM, Scomparin DS, Scarante FF, Santos IP dos, Mechoulam R, Kapczinski F, Fonseca BAL da, Esposito DLA, Lima KP, Sen S, Andraus MH, Hallak JEC. Efficacy and safety of cannabidiol plus standard care vs standard care alone for the treatment of emotional exhaustion and Burnout among frontline health care workers during the COVID-19 pandemic: a randomized clinical trial [Internet]. JAMA Network Open. 2021 ; 4( 8):[citado 2024 jun. 30 ] Available from: https://doi.org/10.1001/jamanetworkopen.2021.20603
Vancouver
Crippa JA de S, Zuardi AW, Guimarães FS, Campos AC de, Osório F de L, Loureiro SR, Santos RG dos, Souza JD dos S, Ushirohira JM, Pacheco JC, Ferreira RR, Costa KCM, Scomparin DS, Scarante FF, Santos IP dos, Mechoulam R, Kapczinski F, Fonseca BAL da, Esposito DLA, Lima KP, Sen S, Andraus MH, Hallak JEC. Efficacy and safety of cannabidiol plus standard care vs standard care alone for the treatment of emotional exhaustion and Burnout among frontline health care workers during the COVID-19 pandemic: a randomized clinical trial [Internet]. JAMA Network Open. 2021 ; 4( 8):[citado 2024 jun. 30 ] Available from: https://doi.org/10.1001/jamanetworkopen.2021.20603
Artigo de periodico
Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test (2019)
Linares, Ila Marques Porto; Zuardi, Antônio Waldo; Pereira, Luis Carlos Bresser; Queiroz, Regina Helena Costa; Mechoulam, Raphael; Guimarães, Francisco Silveira; Crippa, José Alexandre de Souza
Fonte: Brazilian Journal of Psychiatry. Unidades: FMRP, FCFRP
Assuntos: ANSIEDADE, CANABINOIDES, DISCURSO, COMPORTAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LINARES, Ila Marques Porto et al. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Brazilian Journal of Psychiatry, v. 41, n. 1, p. 9-14, 2019Tradução . . Disponível em: https://doi.org/10.1590/1516-4446-2017-0015. Acesso em: 30 jun. 2024.
APA
Linares, I. M. P., Zuardi, A. W., Pereira, L. C. B., Queiroz, R. H. C., Mechoulam, R., Guimarães, F. S., & Crippa, J. A. de S. (2019). Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Brazilian Journal of Psychiatry, 41( 1), 9-14. doi:10.1590/1516-4446-2017-0015
NLM
Linares IMP, Zuardi AW, Pereira LCB, Queiroz RHC, Mechoulam R, Guimarães FS, Crippa JA de S. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test [Internet]. Brazilian Journal of Psychiatry. 2019 ; 41( 1): 9-14.[citado 2024 jun. 30 ] Available from: https://doi.org/10.1590/1516-4446-2017-0015
Vancouver
Linares IMP, Zuardi AW, Pereira LCB, Queiroz RHC, Mechoulam R, Guimarães FS, Crippa JA de S. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test [Internet]. Brazilian Journal of Psychiatry. 2019 ; 41( 1): 9-14.[citado 2024 jun. 30 ] Available from: https://doi.org/10.1590/1516-4446-2017-0015
Artigo de periodico
Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative (2017)
Silva, Nicole R.; Gomes, Felipe V.; Fonseca, Miriam D.; Mechoulam, Raphael; Breuer, Aviva; Cunha, Thiago Mattar; Guimarães, Francisco Silveira
Fonte: Progress in Neuro-Psychopharmacology and Biological Psychiatry. Unidade: FMRP
Assuntos: CANABINOIDES, ANALGÉSICOS, NOCICEPTORES, MODELOS ANIMAIS DE DOENÇAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Nicole R. et al. Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative. Progress in Neuro-Psychopharmacology and Biological Psychiatry, v. 79, p. 369-377, 2017Tradução . . Disponível em: https://doi.org/10.1016/j.pnpbp.2017.07.012. Acesso em: 30 jun. 2024.
APA
Silva, N. R., Gomes, F. V., Fonseca, M. D., Mechoulam, R., Breuer, A., Cunha, T. M., & Guimarães, F. S. (2017). Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 79, 369-377. doi:10.1016/j.pnpbp.2017.07.012
NLM
Silva NR, Gomes FV, Fonseca MD, Mechoulam R, Breuer A, Cunha TM, Guimarães FS. Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative [Internet]. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2017 ; 79 369-377.[citado 2024 jun. 30 ] Available from: https://doi.org/10.1016/j.pnpbp.2017.07.012
Vancouver
Silva NR, Gomes FV, Fonseca MD, Mechoulam R, Breuer A, Cunha TM, Guimarães FS. Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative [Internet]. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2017 ; 79 369-377.[citado 2024 jun. 30 ] Available from: https://doi.org/10.1016/j.pnpbp.2017.07.012
Artigo de periodico
Correction: Fluorinated cannabidiol derivatives: enhancement of activity in mice models predictive of anxiolytic, antidepressant and antipsychotic effects (2016)
Breuer, Aviva; Haj, Christeene G.; Fogaça, Manoela V.; Gomes, Felipe V.; Silva, Nicole Rodrigues; Pedrazzi, João Francisco; Del Bel, Elaine Aparecida; Hallak, Jaime Eduardo Cecílio; Crippa, José Alexandre de Souza; Zuardi, Antônio Waldo; Mechoulam, Raphael; Guimarães, Francisco Silveira
Fonte: PLOS ONE. Unidades: FORP, FMRP
Assuntos: CANABINOIDES, FLUORAÇÃO, NEUROPSIQUIATRIA, FARMACOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BREUER, Aviva et al. Correction: Fluorinated cannabidiol derivatives: enhancement of activity in mice models predictive of anxiolytic, antidepressant and antipsychotic effects. PLOS ONE, v. 11, n. 8, 2016Tradução . . Disponível em: https://doi.org/10.1371/journal.pone.0162087. Acesso em: 30 jun. 2024.
APA
Breuer, A., Haj, C. G., Fogaça, M. V., Gomes, F. V., Silva, N. R., Pedrazzi, J. F., et al. (2016). Correction: Fluorinated cannabidiol derivatives: enhancement of activity in mice models predictive of anxiolytic, antidepressant and antipsychotic effects. PLOS ONE, 11( 8). doi:10.1371/journal.pone.0162087
NLM
Breuer A, Haj CG, Fogaça MV, Gomes FV, Silva NR, Pedrazzi JF, Del Bel EA, Hallak JEC, Crippa JA de S, Zuardi AW, Mechoulam R, Guimarães FS. Correction: Fluorinated cannabidiol derivatives: enhancement of activity in mice models predictive of anxiolytic, antidepressant and antipsychotic effects [Internet]. PLOS ONE. 2016 ; 11( 8):[citado 2024 jun. 30 ] Available from: https://doi.org/10.1371/journal.pone.0162087
Vancouver
Breuer A, Haj CG, Fogaça MV, Gomes FV, Silva NR, Pedrazzi JF, Del Bel EA, Hallak JEC, Crippa JA de S, Zuardi AW, Mechoulam R, Guimarães FS. Correction: Fluorinated cannabidiol derivatives: enhancement of activity in mice models predictive of anxiolytic, antidepressant and antipsychotic effects [Internet]. PLOS ONE. 2016 ; 11( 8):[citado 2024 jun. 30 ] Available from: https://doi.org/10.1371/journal.pone.0162087
Artigo de periodico
Fluorinated Cannabidiol derivatives: enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects (2016)
Breuer, Aviva; Haj, Christeene G.; Fogaça, Manoela V.; Gomes, Felipe V.; Silva, Nicole Rodrigues; Pedrazzi, João Francisco; Del Bel, Elaine Aparecida; Hallak, Jaime Eduardo Cecílio; Crippa, José Alexandre de Souza; Zuardi, Antônio Waldo; Mechoulam, Raphael; Guimarães, Francisco Silveira
Fonte: PLOS ONE. Unidades: FORP, FMRP
Assuntos: CANABINOIDES, FLUORAÇÃO, NEUROPSIQUIATRIA, FARMACOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BREUER, Aviva et al. Fluorinated Cannabidiol derivatives: enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects. PLOS ONE, v. 11, 2016Tradução . . Disponível em: https://doi.org/10.1371/journal.pone.0158779. Acesso em: 30 jun. 2024.
APA
Breuer, A., Haj, C. G., Fogaça, M. V., Gomes, F. V., Silva, N. R., Pedrazzi, J. F., et al. (2016). Fluorinated Cannabidiol derivatives: enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects. PLOS ONE, 11. doi:10.1371/journal.pone.0158779
NLM
Breuer A, Haj CG, Fogaça MV, Gomes FV, Silva NR, Pedrazzi JF, Del Bel EA, Hallak JEC, Crippa JA de S, Zuardi AW, Mechoulam R, Guimarães FS. Fluorinated Cannabidiol derivatives: enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects [Internet]. PLOS ONE. 2016 ; 11[citado 2024 jun. 30 ] Available from: https://doi.org/10.1371/journal.pone.0158779
Vancouver
Breuer A, Haj CG, Fogaça MV, Gomes FV, Silva NR, Pedrazzi JF, Del Bel EA, Hallak JEC, Crippa JA de S, Zuardi AW, Mechoulam R, Guimarães FS. Fluorinated Cannabidiol derivatives: enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects [Internet]. PLOS ONE. 2016 ; 11[citado 2024 jun. 30 ] Available from: https://doi.org/10.1371/journal.pone.0158779

Unidades USP

ReP

Filtros

Departamento

Autores

Autores USP

Assuntos

Título da fonte

Agência de fomento

Indexado em

Afiliação dos autores externos não normalizada